Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

10.28 +0.31 (+3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
From NeoGenomics, Inc.
Via Business Wire
A Look at NeoGenomics's Upcoming Earnings Report
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
From NeoGenomics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences. 
Via Benzinga
Topics Artificial Intelligence
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
3 Hot Trades for Insiders, But Are They Good Buys for Investors?
Insiders are buying Hudson Pacific Properties and NeoGenomics, but selling Carvana. These trends will likely continue in 2025. 
Via MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
From NeoGenomics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
3 Cash-Burning Stocks Facing Headwinds
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
3 Unprofitable Stocks in Hot Water
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
3 Volatile Stocks in Hot Water
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via Business Wire
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could... 
Via StockStory
Topics Bonds Stocks
NeoGenomics to Participate in Upcoming June Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
3 Healthcare Stocks with Mounting Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
3 Russell 2000 Stocks in the Doghouse
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Assessing NeoGenomics: Insights From 9 Financial Analysts
 
Via Benzinga
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play. 
Via MarketBeat
Topics World Trade
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
NeoGenomics Pays Off 1.25% Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.